002462 Cachet Pharmaceutical
- 10.84
- +0.15+1.40%
Cachet Pharmaceutical News
Kashitang (002462): the performance is in line with the expected substantial increase in the proportion of major shareholders.
Jiashitang (002462): rapid growth of equipment Wholesale Business and remarkable improvement in operating efficiency
Jiashitang (002462): good performance and rapid development of outport business
Ka Shitang (002462): the performance is in line with the expected outport business to maintain rapid development.
Jiashitang (002462): smooth transition of business in Beijing area and continuous development of business in other areas.
Jiashitang (002462) Quarterly Report Review: Growth in the third quarter was in line with expectations, consumables distribution progressed steadily
Comment on Jiashitang (002462) Quarterly report: the performance is in line with expectations and actively promote the layout of outport business.
Jiashitang (002462): the performance is in line with the expected development momentum of the equipment business.
Jiashitang (002462) quarterly report comments: the third quarter performance growth is good, the company's value is obviously undervalued.
Jiashitang (002462) in-depth study: medical Reform promotes the Integration of Drug Wholesale consumables with clear prospects
嘉事堂(002462)中报点评：上半年业绩维持快速增长 持续拓展外埠业务
嘉事堂(002462)：二季度业绩提速 外延扩张整合成效显现
嘉事堂(002462)半年报点评：器械配送龙头、业绩持续稳定增长
嘉事堂(002462)半年报点评：增速符合预期北京地区表现较好
嘉事堂(002462)半年报点评：业绩逐步回暖 全国布局稳步推行
嘉事堂(002462)半年报点评：北京地区受益阳光采购 全国扩张稳步推进
嘉事堂(002462)中报点评：二季度增长加速 半年内生业绩表现良好
嘉事堂(002462)半年报点评：药品器械双轮驱动 业绩高速增长
嘉事堂(002462)年报点评：收入高增长 看好全国扩张
嘉事堂(002462)2017年报及2018年一季报点评：业绩基本符合预期 外延拓展持续
Analysis
Price Target
No Data
